



COPY OF PAPERS
ORIGINALLY FILED

PATENTS

Attorney Docket No. 25352-0022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

First Inventor Name: Hugo O. Villar

App. No.: 10/082,801

Filing Date: February 22, 2002

For: ACRIDINES AS STIMULATORS FOR FAS-MEDIATED APOPTOSIS

Commissioner for Patents
Washington, D.C. 20231

Sir:

POWER OF ATTORNEY BY ASSIGNEE
AND STATEMENT UNDER 37 CFR 3.73

Telik, Inc. ("Telik") states that it is the assignee of the entire right, title and interest in the application identified above by virtue of an assignment from the inventors, a copy of which is attached hereto.

As assignee of the entire interest of the above identified application, Telik hereby appoints the practitioners at Customer Number 25213 as its attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

The undersigned is authorized to act on behalf of the assignee.

Telik, Inc.

By:


Michael M. Wick
President, CEO & Chairman

Date: April 23, 2002

COPY OF PAPERS
ORIGINALLY FILED

WHEREAS, We, Hugo O. Villar and Edgardo Laborde of certain subject matter entitled ACRIDINES AS STIMULATORS FOR FAS-MEDIATED APOPTOSIS (the "Invention"), for which has been filed U.S. Patent Application No. 10/082,801, filed in the U.S. Patent & Trademark Office on February 22, 2002;

AND WHEREAS, Telik, Inc., having an address at 750 Gateway Boulevard, South San Francisco, California 94080 ("Telik") desires to perfect its right to the Invention and in the Letters Patent to be obtained therefor from the United States of America;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, We acknowledge Telik's interest in the Invention and hereby assign to Telik for the United States of America and for all countries foreign thereto, all our rights, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in the Invention, as described and claimed in Application No. 10/082,801, or in any continuation, division, reissue, reexamination or extension thereof and any legal equivalent thereof in a country foreign to the United States of America; the Invention, application and Letters Patent to be owned by Telik, its successors, assigns and legal representatives, to the full end of the term for which such Letters Patent may be granted.

This assignment is effective as of February 22, 2002.


I have read and understand this Assignment document for Application No. 10/082,801 and agree hereto, as indicated by my signature as set forth below.

FIRST JOINT INVENTOR

INVENTOR'S SIGNATURE

DATE

Hugo O. Villar



4/18/2002

SECOND JOINT INVENTOR

INVENTOR'S SIGNATURE

DATE

Edgardo Laborde

351296 v01.SV (7j28011.DOC)
3/26/02 11:04 AM (25352.0022)

**COPY OF PAPERS
ORIGINALLY FILED**

COPY OF PAPERS
ORIGINALLY FILED

WHEREAS, We, Hugo O. Villar and Edgardo Laborde of certain subject matter entitled ACRIDINES AS STIMULATORS FOR FAS-MEDIATED APOPTOSIS (the "Invention"), for which has been filed U.S. Patent Application No. 10/082,801, filed in the U.S. Patent & Trademark Office on February 22, 2002;

AND WHEREAS, Telik, Inc., having an address at 750 Gateway Boulevard, South San Francisco, California 94080 ("Telik") desires to perfect its right to the Invention and in the Letters Patent to be obtained therefor from the United States of America;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, We acknowledge Telik's interest in the Invention and hereby assign to Telik for the United States of America and for all countries foreign thereto, all our rights, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in the Invention, as described and claimed in Application No. 10/082,801, or in any continuation, division, reissue, reexamination or extension thereof and any legal equivalent thereof in a country foreign to the United States of America; the Invention, application and Letters Patent to be owned by Telik, its successors, assigns and legal representatives, to the full end of the term for which such Letters Patent may be granted.

This assignment is effective as of February 22, 2002.